

# Xencor Collaboration with MD Anderson

## Client News

January 7, 2021

Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its collaboration agreement with MD Anderson to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

In the [announcement of the transaction](#), SVP and chief science officer of Xencor John Desjarlais said, “Xencor’s modular antibody engineering platform enables the rapid generation of XmAb bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer.”

The Gunderson deal team was led by Brendan McCarthy.

## Related People



Brendan C. McCarthy

PARTNER

P +1 858 436 8013

## Featured Insights

### CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

### FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

### CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

### CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

### CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

### CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

### CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

### CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

### CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

### INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

## CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

## INSIGHTS

Client Insight: California AI Transparency Act